MILD COGNITIVE IMPAIRMENT TREATMENT - AN OVERVIEW

Mainly because individuals who carry the APOE e4 gene variant appear to have a greater hazard of serious troubles, the FDA endorses being tested with the gene variant before starting treatment with lecanemab or donanemab.Practical and ecologically legitimate efficiency-centered steps of IADLs may also be confined. The Neuropsychological Evaluation